Analyzing Daxor (NASDAQ:DXR) & Chemed (NYSE:CHE)

Chemed (NYSE:CHE) and Daxor (NASDAQ:DXR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation.

Earnings & Valuation

This table compares Chemed and Daxor”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.43 billion	2.65	$302.00 million	$19.45	22.76
Daxor	N/A	N/A	N/A	N/A	N/A

Chemed has higher revenue and earnings than Daxor.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Chemed and Daxor, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0	1	4	0	2.80
Daxor	0	1	1	0	2.50

Chemed currently has a consensus price target of $578.50, suggesting a potential upside of 30.66%. Daxor has a consensus price target of $25.00, suggesting a potential upside of 79.86%. Given Daxor’s higher possible upside, analysts plainly believe Daxor is more favorable than Chemed.

Profitability

This table compares Chemed and Daxor’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Chemed	11.56%	25.83%	17.77%
Daxor	N/A	N/A	N/A

Volatility & Risk

Chemed has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Daxor has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500.

Institutional and Insider Ownership

95.9% of Chemed shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 3.3% of Chemed shares are held by company insiders. Comparatively, 59.5% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Chemed beats Daxor on 8 of the 10 factors compared between the two stocks.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.